drugset / Trial / NCT03351569

Intravenous Immunoglobulin for Unverricht-Lundborg Disease.

NCT03351569

RandomizedCrossoverQuadruple-blindTreatment

Summary

Single patient randomized double blind trial to assess whether intravenous immunoglobulin can improve the clinical outcome of a case suffering from Unverricht-Lundborg disease.

Timeline

Start
2015-12-09
Primary completion
2016-12-06
Completion
2017-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Immune Globulin Intravenous (Human) Protein / enzyme biologic 25 g Intravenous